×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CNTX – context therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CNTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/6
04:22 pm
cntx
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Medium
Report
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results [Yahoo! Finance]
11/6
04:06 pm
cntx
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Medium
Report
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
10/23
07:30 am
cntx
Context Therapeutics to Participate in Upcoming Investor Conferences in November
Medium
Report
Context Therapeutics to Participate in Upcoming Investor Conferences in November
10/16
07:30 am
cntx
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Medium
Report
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
9/23
02:05 pm
cntx
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
9/23
07:30 am
cntx
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Medium
Report
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
9/16
09:09 am
cntx
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth [Yahoo! Finance]
Low
Report
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth [Yahoo! Finance]
9/16
08:03 am
cntx
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/15
06:13 am
cntx
Form EFFECT Context Therapeutics
Neutral
Report
Form EFFECT Context Therapeutics
11/14
05:31 pm
cntx
Form SC 13G/A Context Therapeutics Filed by: Avidity Partners Management LP
Medium
Report
Form SC 13G/A Context Therapeutics Filed by: Avidity Partners Management LP
11/14
05:05 pm
cntx
Form SC 13G Context Therapeutics Filed by: Blue Owl Capital Holdings LP
Medium
Report
Form SC 13G Context Therapeutics Filed by: Blue Owl Capital Holdings LP
11/14
04:53 pm
cntx
Form SC 13G/A Context Therapeutics Filed by: GREAT POINT PARTNERS LLC
Medium
Report
Form SC 13G/A Context Therapeutics Filed by: GREAT POINT PARTNERS LLC
11/6
05:08 pm
cntx
Form SC 13G/A Context Therapeutics Filed by: Hudson Bay Capital Management LP
Medium
Report
Form SC 13G/A Context Therapeutics Filed by: Hudson Bay Capital Management LP
11/6
04:03 pm
cntx
Form 10-Q Context Therapeutics For: Sep 30
Medium
Report
Form 10-Q Context Therapeutics For: Sep 30
9/23
07:33 am
cntx
Form 8-K Context Therapeutics For: Sep 23
High
Report
Form 8-K Context Therapeutics For: Sep 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: